Pruritus after discontinuation of cetirizine

Background: Intense pruritus or itching emerging after discontinuation of cetirizine has been the subject of postmarketing reports submitted to the U.S. Food and Drug Administration (FDA), published in the medical literature, and discussed on the internet. To better understand and further investigat...

Full description

Bibliographic Details
Main Authors: Amy H. Chung, Lois La Grenade, Lisa M. Harinstein
Format: Article
Language:English
Published: SAGE Publishing 2019-07-01
Series:Therapeutic Advances in Drug Safety
Online Access:https://doi.org/10.1177/2042098619859996
id doaj-230eed47061c4df09706d9ec2eac1e2c
record_format Article
spelling doaj-230eed47061c4df09706d9ec2eac1e2c2020-11-25T03:32:43ZengSAGE PublishingTherapeutic Advances in Drug Safety2042-09942019-07-011010.1177/2042098619859996Pruritus after discontinuation of cetirizineAmy H. ChungLois La GrenadeLisa M. HarinsteinBackground: Intense pruritus or itching emerging after discontinuation of cetirizine has been the subject of postmarketing reports submitted to the U.S. Food and Drug Administration (FDA), published in the medical literature, and discussed on the internet. To better understand and further investigate this adverse event, we analyzed cases of pruritus occurring after discontinuation of cetirizine in the FDA Adverse Event Reporting System (FAERS) database and medical literature. Methods: We conducted a retrospective study to identify and describe cases of pruritus occurring after discontinuation of cetirizine in the FAERS database and medical literature through April 24, 2017. Data collected from the reports included demographic information, reason for use, serious outcome, report source, duration of cetirizine use, time to onset of pruritus after cetirizine discontinuation, presence of associated urticaria, treatment for pruritus, concomitant comorbidities and medications associated with pruritus, rechallenge information, and patient outcome information. Results: We identified 146 cases of pruritus after discontinuation of cetirizine. Reporting frequency increased starting in 2008. The median patient age was 38 years ( n  = 141), ranging from 6 to 71 years, and cases were predominantly reported in females ( n  = 110). Most cases ( n  = 115) were submitted directly to the FDA from consumers or healthcare providers. The median duration of use of cetirizine prior to discontinuation was 24 months ( n  = 130), ranging from 0.3 to 172.2 months. The median time to onset of pruritus from discontinuation was 2 days ( n  = 91), ranging from 0.5 to 5 days. Of the 55 cases that reported discontinuation of cetirizine again after restarting, 54 reported pruritus recurrence. Conclusions: Our case series provided evidence of an association between the discontinuation of cetirizine and the development of pruritus. The mechanism by which cetirizine causes pruritus upon discontinuation is unknown. Patients and prescribers should have knowledge of this adverse event, given the widespread use and availability of cetirizine, and potential impact on patient quality of life.https://doi.org/10.1177/2042098619859996
collection DOAJ
language English
format Article
sources DOAJ
author Amy H. Chung
Lois La Grenade
Lisa M. Harinstein
spellingShingle Amy H. Chung
Lois La Grenade
Lisa M. Harinstein
Pruritus after discontinuation of cetirizine
Therapeutic Advances in Drug Safety
author_facet Amy H. Chung
Lois La Grenade
Lisa M. Harinstein
author_sort Amy H. Chung
title Pruritus after discontinuation of cetirizine
title_short Pruritus after discontinuation of cetirizine
title_full Pruritus after discontinuation of cetirizine
title_fullStr Pruritus after discontinuation of cetirizine
title_full_unstemmed Pruritus after discontinuation of cetirizine
title_sort pruritus after discontinuation of cetirizine
publisher SAGE Publishing
series Therapeutic Advances in Drug Safety
issn 2042-0994
publishDate 2019-07-01
description Background: Intense pruritus or itching emerging after discontinuation of cetirizine has been the subject of postmarketing reports submitted to the U.S. Food and Drug Administration (FDA), published in the medical literature, and discussed on the internet. To better understand and further investigate this adverse event, we analyzed cases of pruritus occurring after discontinuation of cetirizine in the FDA Adverse Event Reporting System (FAERS) database and medical literature. Methods: We conducted a retrospective study to identify and describe cases of pruritus occurring after discontinuation of cetirizine in the FAERS database and medical literature through April 24, 2017. Data collected from the reports included demographic information, reason for use, serious outcome, report source, duration of cetirizine use, time to onset of pruritus after cetirizine discontinuation, presence of associated urticaria, treatment for pruritus, concomitant comorbidities and medications associated with pruritus, rechallenge information, and patient outcome information. Results: We identified 146 cases of pruritus after discontinuation of cetirizine. Reporting frequency increased starting in 2008. The median patient age was 38 years ( n  = 141), ranging from 6 to 71 years, and cases were predominantly reported in females ( n  = 110). Most cases ( n  = 115) were submitted directly to the FDA from consumers or healthcare providers. The median duration of use of cetirizine prior to discontinuation was 24 months ( n  = 130), ranging from 0.3 to 172.2 months. The median time to onset of pruritus from discontinuation was 2 days ( n  = 91), ranging from 0.5 to 5 days. Of the 55 cases that reported discontinuation of cetirizine again after restarting, 54 reported pruritus recurrence. Conclusions: Our case series provided evidence of an association between the discontinuation of cetirizine and the development of pruritus. The mechanism by which cetirizine causes pruritus upon discontinuation is unknown. Patients and prescribers should have knowledge of this adverse event, given the widespread use and availability of cetirizine, and potential impact on patient quality of life.
url https://doi.org/10.1177/2042098619859996
work_keys_str_mv AT amyhchung pruritusafterdiscontinuationofcetirizine
AT loislagrenade pruritusafterdiscontinuationofcetirizine
AT lisamharinstein pruritusafterdiscontinuationofcetirizine
_version_ 1724566377775235072